Delaware BioScience Association (Delaware Bio)announcedthat Michael Fleming will become the organization’s nextPresident effective today. He succeeds Helen Stimson who has led theorganization since 2017.
“Continuity in leadership during the current environment is vital to both our membercompanies and our mission to support the life science ecosystem in Delaware. Weconsider ourselves incredibly fortunate that Michael Fleming, a proven strategicleader with deep roots in Delaware, will become the new President of Delaware Bio.Michael’s experience with life science companies and his expertise in marketing,branding, communications, and public policy will be of great value as we strive tofind new and effective ways to support our members,” stated Christopher Yochim,chairman of Delaware Bio’s Board of Directors andhead of Business Development at National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Fran DiNuzzo. CEO of the spacesuit and protective equipment maker ILC Dover, and a member of Delaware Bio’s Boardof Directors, added, “Importantly, Michael is appreciative of the many challengesand diverse needs of our members and recognizes the critical role these companiesplay in growing and supporting Delaware’s economy and public health. Given hisdemonstrated solution-minded approach to business challenges, his high energyand enthusiasm for making a difference in Delaware, and his ability to create anddrive high performing teams, we are confident that with his leadership Delaware Biowill retain its reputation as a valued partner and dedicated advocate for ourcommunity of life science companies.”
Fleming is a senior biopharmaceutical industry executive with global experience in strategy, marketing, communications, corporate socialresponsibility, community program development, public policy, and publishing.
Hespent 18 years at the global biopharmaceutical company GSK, most recently asHead of Global Medical and Regulatory Communications.
Fleming stated, “I amhonored and excited to lead thisoutstanding organization. There hasnever been a time when theextraordinary value of Delaware Biomembers has been more clear. Atthis moment, great companies andresearchers right here aredeveloping and manufacturingtreatments and vaccines, newtesting technologies and criticalsafety equipment to address theglobal pandemic – among so manyother advances. Delaware’s healthand economic future depend onensuring this state is the mostdynamic, attractive hub in thecountry for scientific innovation.”
Helen Stimson, chief operating officer of Adesis, Inc., and former President ofDelaware Bio, stated, “I am grateful to have had the opportunity to work with somany innovative scientists, clinicians and dedicated business professionals allfocused on improving the lives of patients, our food supply, our environment and thehealth and well-being of the general public. Their work is hugely important toDelaware on multiple fronts and I am confident that Michael is the right person tolead the organization and that he will continue to strengthen its resources, relevanceand influence.”
Fleming began his career as an aide to the late US Senator William V. Roth, Jr., firstas a legislative assistant on Capitol Hill and then as the senator’s Wilmington stateoffice director. He has served on multiple boards and committees with organizationsincluding the Children’s Health Fund, The Barnes Foundation, West EndNeighborhood House, St. Patrick’s Day Society, Delaware Adolescent Program Inc. and theUniversity of Delaware Alumni Association.
Fleming is a graduate of Salesianum School, the University of Delaware, and JohnsHopkins School of Advanced International Studies.
Fleming and his wife Christy Eagleton Fleming have threechildren and live in Wilmington.
Delaware Bio’s members include pharmaceutical and biotechnology firms, medical device manufacturers, agricultural biotech and chemical companies, research and testing companies, hospitals and medical institutions, and other organizations and related service companies.
Its 130 member companies and organizations represent 8,000 Delaware jobs.